Pharmaceutical composition containing mitophagy inducer

By selecting incompatible excipients in the pharmaceutical composition, a pharmaceutical composition containing TJ0113 was developed, which solved the incompatibility problem of TJ0113 and excipients, and achieved the stability and long-term storage of the formulation.

WO2025077724A1PCT designated stage expired Publication Date: 2025-04-17HANGZHOU PHECDAMED CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/123604
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-19
Filing Date
2024-10-09
Publication Date
2025-04-17

AI Technical Summary

Technical Problem

In the prior art, the mitochondrial autophagy inducer compound TJ0113 is prone to stability problems when prepared into a preparation, and is prone to interact with a variety of excipients, resulting in incompatibility and affecting long-term storage.

Method used

A pharmaceutical composition containing TJ0113 was developed to avoid incompatibility problems by selecting diluents, disintegrants and lubricants that do not interact with TJ0113, such as microcrystalline cellulose, pregelated starch, sodium carboxymethyl starch and sodium stearyl fumarate.

Benefits of technology

The stability of TJ0113 compound is achieved, the long-term storage and dissolution performance of the preparation are ensured, and the incompatibility problem between TJ0113 and auxiliary materials in the prior art is solved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024123604-FTAPPB-I100001
    Figure PCTCN2024123604-FTAPPB-I100001
  • Figure PCTCN2024123604-FTAPPB-I100002
    Figure PCTCN2024123604-FTAPPB-I100002
  • Figure PCTCN2024123604-FTAPPB-I100003
    Figure PCTCN2024123604-FTAPPB-I100003
Patent Text Reader

Abstract

A pharmaceutical composition containing a mitophagy inducer as an active substance. The pharmaceutical composition is conducive to being prepared into a pharmaceutical preparation, can avoid incompatibility caused by the interaction between the active substance and an auxiliary material, and thus can be stored for a long period of time.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical compositions comprising mitochondrial autophagy inducers Technical Field

[0001] The present invention relates to a pharmaceutical composition comprising a mitochondrial autophagy inducer, and belongs to the field of pharmaceutical preparations. Background Art

[0002] The compound of Formula I and its specific compound (particularly TJ0113) are described in CN115894404A and are mitophagy inducers that can be used to inhibit or alleviate various acute or chronic diseases caused by mitophagy dysfunction. The general formula and the structure of compound TJ0113 are as follows:

[0003] The prior art does not include any research on pharmaceutical compositions or formulations of this compound. The inventors of this application have discovered that this mitophagy inducer compound is prone to stability issues when formulated into a formulation. This is because the compound easily interacts with a variety of excipients commonly used in the pharmaceutical industry, resulting in incompatibility and hindering long-term storage. Therefore, there is an urgent need in the art to develop a pharmaceutical composition that can address the incompatibility issue between the mitophagy inducer compound and excipients, thereby enabling the production of a formulation that can be stored for a long time.

[0004] Summary of the Invention

[0005] The inventors of this application have conducted extensive research to address the aforementioned issues and have developed a pharmaceutical composition comprising a mitophagy inducer that can overcome the incompatibility issue. Specifically, the present invention includes but is not limited to the following technical contents:

[0006] 1. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, a diluent, a disintegrant, and a lubricant, and excluding any of the following ingredients: hydroxypropyl cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, talc, mannitol, and croscarmellose sodium.

[0007] Where, R 2 is hydrogen, C 1~4 Alkyl, C 3~6 Cycloalkyl, four- to six-membered epoxyalkyl;

[0008] R 3 for

[0009] Among them, R 3-1 For hydrogen, hydroxyl, C 1~4 Alkyl, C 1~4 Alkoxy, C 3~6 Cycloalkyl, three to six-membered epoxyalkyl, -N(R3 - 2 R 3 - 2a )、-CH2C(O)R 3-2 、-CH2C(O)OR 3-2 、-CH2C(O)NR 3-2 R 3-2a ,

[0010] R 3-2 and R 3-2a are independently hydrogen, C 1~4 an alkyl group or a three- to six-membered cycloalkyl group,

[0011] Ar is phenyl, 5- or 6-membered monocyclic heteroaryl, or is supported by at least one R 3-3 substituted 5- or 6-membered monocyclic heteroaryl, wherein R 3-3 For hydrogen, halogen, C 1~4 Alkyl, three to six-membered cycloalkyl, hydroxyl, C 1~4 Alkoxy, three to six-membered epoxyalkyl, C 1~4 Halogenated alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, -N(R 3-3a R 3-3b ) or phenyl,

[0012] R 3-3a and R 3-3b are independently hydrogen, C 1~4 Alkyl or three to six-membered cycloalkyl;

[0013] R 4 for

[0014] Among them, R 4-1 is phenyl, at least one R 4-11 Substituted phenyl, 5 or 6 membered monocyclic heteroaryl, at least one R 4- 11 substituted 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heteroaryl, at least one R 4-11 substituted 8- to 10-membered fused bicyclic heteroaryl, wherein R 4-11 Halogen, nitro, C 1~4 Alkyl, C 3~6 Cycloalkyl, C 1~4 Alkoxy, -N(R 4-1a R 4- 1b ), phenyl, C 1~4 Halogenated alkyl, C 1~4 Haloalkoxy or R 4-1a and R 4-1b are each independently hydrogen, C 1~4 Alkyl or C 3~6 Cycloalkyl, and R 4-1a and R 4-1b Can bond to each other to form a ring,

[0015] R 4-2 C 1~4 Alkyl, C 3~6 Cycloalkyl, or when R 2 C 1~4 When alkyl, R 4-2 With R 2 Bonded to form a 4- to 8-membered ring,

[0016] R 4-3 C 1~4 Alkyl or C 1~4 alkoxy;

[0017] R 5 The number of R is 0 to 5. 5 When the number is not 0, each is independently selected from halogen, nitro, nitrile, -N + (R 5-1 )3. C 1~4 Haloalkyl, -C(O)OR 5-1 、-C(O)R 5-1 、-C(O)N(R 5-1 R 5-1a )、-S(O)2R 5-1 、-S(O)R 5-1 、-N=C(R 5- 1 R 5-1a ), hydroxyl, C 1~4 Alkyl, phenyl, at least one hydrogen is replaced by R 5-1 Substituted phenyl, C 1~4 Alkoxy, -N(R 5-1 R 5-1 a), -N(R 5-1 )C(O)R 5-1a 、-OC(O)R 5-1 、-OC(O)N(R 5-1 R 5-1a ) or -SR 5-1 , where R 5-1 、R 5-1a and R 5-1 b are each independently hydrogen, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C in which at least one hydrogen is replaced by halogen 1~4 Alkyl, C in which at least one hydrogen is replaced by a halogen 2~4Alkenyl or C in which at least one hydrogen is replaced by halogen 2~4 Alkynyl.

[0018] 2. The pharmaceutical composition according to technical content 1, wherein the diluent comprises microcrystalline cellulose and pregelatinized starch.

[0019] 3. The pharmaceutical composition according to technical content 1 or 2, wherein the disintegrant is sodium starch glycolate.

[0020] 4. The pharmaceutical composition according to any one of technical contents 1-3, wherein the lubricant is sodium stearyl fumarate.

[0021] 5. The pharmaceutical composition according to any one of technical contents 1-4, wherein R 2 is hydrogen or C 1~4 alkyl;

[0022] R 3 for

[0023] Among them, R 3-1 For hydrogen, hydroxyl, C 1~4 Alkyl or C 1~4 Alkoxy,

[0024] R 4 for

[0025] Among them, R 4-1 is phenyl, at least one R 4-11 Substituted phenyl, 5 or 6 membered monocyclic heteroaryl, at least one R 4- 11 substituted 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heteroaryl, at least one R 4-11 substituted 8- to 10-membered fused bicyclic heteroaryl, wherein R 4-11 Halogen, nitro, C 1~4 Alkyl, C 3~6 Cycloalkyl, C 1~4 Alkoxy, -N(R 4-1a R 4- 1b ), phenyl, C 1~4 Halogenated alkyl, C 1~4 Haloalkoxy or R 4-1a and R 4-1 b are each independently hydrogen, C 1~4 Alkyl or C 3~6 Cycloalkyl, and R 4-1a and R 4-1b Can bond to each other to form a ring,

[0026] R 4-2C 1~4 Alkyl, C 3~6 Cycloalkyl, or when R 2 C 1~4 When alkyl, R 4-2 With R 2 Bonded to form a 4- to 8-membered ring,

[0027] R 4-3 C 1~4 Alkyl or C 1~4 alkoxy;

[0028] R 5 The number of R is 0 to 3, 5 When the number is not 0, each is independently selected from halogen, nitro, nitrile, -N + (R 5-1 )3. C 1~4 Haloalkyl, -C(O)OR 5-1 、-C(O)R 5-1 、-C(O)N(R 5-1 R 5-1a )、-S(O)2R 5-1 、-S(O)R 5-1 、-N=C(R 5- 1 R 5-1a ), hydroxyl, C 1~4 Alkyl, phenyl, at least one hydrogen is replaced by R 5-1 Substituted phenyl, C 1~4 Alkoxy, -N(R 5-1 R 5-1a )、-N(R 5-1 )C(O)R 5-1a 、-OC(O)R 5-1 、-OC(O)N(R 5-1 R 5-1a ) or -SR 5-1 , where R 5-1 、R 5-1a and R 5-1b are independently hydrogen, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C in which at least one hydrogen is replaced by halogen 1~4 Alkyl, C in which at least one hydrogen is replaced by a halogen 2~4 Alkenyl or C in which at least one hydrogen is replaced by halogen 2~4 Alkynyl.

[0029] 6. The pharmaceutical composition according to technical content 5, wherein R 2 is hydrogen or C 1~4 alkyl,

[0030] R 3 for R 3-1 Hydroxyl or C 1~4 Alkoxy,

[0031] R 4 for

[0032] Among them, R 4-1 is phenyl, at least one R 4-11 substituted phenyl, 5- or 6-membered monocyclic heteroaryl, or at least one R 4-11 substituted 5- or 6-membered monocyclic heteroaryl, wherein R 4-11 Halogen, nitro, C 1~4 Alkyl, C 3~6 Cycloalkyl, C 1~4 Alkoxy, or C 1~4 haloalkyl; and

[0033] R 5 The number of is 0.

[0034] 7. The pharmaceutical composition according to technical content 6, wherein R 2 For hydrogen,

[0035] R 3 for R 3-1 is hydroxyl group,

[0036] R 4 for

[0037] Among them, R 4-1 For at least one R 4-11 Substituted phenyl, the R 4-11 Halogen, C 1~4 Alkyl, C 1~4 Alkoxy, or C 1~4 haloalkyl; and

[0038] R 5 The number of is 0.

[0039] 8. The pharmaceutical composition according to technical content 7, wherein the compound of formula I is TJ0113

[0040] 9. The pharmaceutical composition according to technical content 8, wherein the TJ0113 is in the solid form of the sodium salt represented by the following formula:

[0041] Wherein X is 0.1-2, for example 1.

[0042] 10. The pharmaceutical composition according to technical content 9, wherein the X-ray powder diffraction pattern of the solid form shows the following characteristic peaks of 2θ (CuKα ray): 7.06° (±0.2°) and 20.87° (±0.2°).

[0043] 11. A pharmaceutical composition according to any one of technical contents 1-10, comprising compound TJ0113 or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, and sodium stearyl fumarate.

[0044] 12. The pharmaceutical composition according to technical content 11, which is composed of compound TJ0113 or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch, and sodium stearyl fumarate.

[0045] 13. A pharmaceutical composition according to any one of technical contents 1-12, wherein the content percentage of the compound of formula I or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is 1.0wt% to 50wt%, the content percentage of the diluent in the pharmaceutical composition is 30wt% to 90wt%, the content percentage of the disintegrant in the pharmaceutical composition is 0.1wt% to 25wt%, and the content percentage of the lubricant in the pharmaceutical composition is 0.01wt% to 5.0wt%.

[0046] 14. A pharmaceutical preparation comprising the pharmaceutical composition according to any one of technical contents 1-13, wherein the pharmaceutical preparation is selected from tablets, capsules, granules, powders, and pills.

[0047] 15. The pharmaceutical preparation according to technical content 14 is a capsule, which consists of a capsule shell and contents, and the contents are the pharmaceutical composition according to any one of technical contents 1-13.

[0048] Preferably, in the aforementioned technical solution involving the solid form of the sodium salt of compound TJ0113, its X-ray powder diffraction pattern shows at least one characteristic peak selected from 7.06° (±0.2°), 18.07° (±0.2°), 25.02° (±0.2°), 17.58° (±0.2°), 20.87° (±0.2°), 10.54° (±0.2°), and 23.91° (±0.2°) 2θ. More preferably, the solid form of the sodium salt of the compound of formula (I) exhibits at least one (more preferably at least two, more preferably at least three) characteristic peaks in 2θ selected from 7.06° (± 0.2°), 18.07° (± 0.2°), 25.02° (± 0.2°), 17.58° (± 0.2°), 20.87° (± 0.2°), 10.54° (± 0.2°), 23.91° (± 0.2°), 27.65° (± 0.2°), 27.05° (± 0.2°), 21.68° (± 0.2°), and 25.91° (± 0.2°) in the X-ray powder diffraction pattern. More preferably, the solid form of the sodium salt of the compound of formula (I) (also referred to herein as "Form D") exhibits an X-ray powder diffraction pattern substantially the same as Figure 8.

[0049] The Form D solid form of the sodium salt of compound TJ0113 exhibits an endothermic peak at 183.79°C (±3°C) and an exothermic peak at 210.79°C (±3°C) in its differential scanning calorimetry (DSC) curve. The solid form of the sodium salt of the compound of formula (I) of the present invention exhibits a thermogravimetric analysis (DSC) pattern substantially similar to that shown in Figure 9 .

[0050] In some preferred embodiments, the thermogravimetric analysis curve of the Form D solid form of the sodium salt of the compound TJ0113 shows a thermogravimetric analysis curve pattern substantially the same as that in FIG10 .

[0051] In some preferred embodiments, the pharmaceutical composition includes the following components in parts by weight:

[0052] 20-30 parts of a compound of formula (I) or a pharmaceutically acceptable salt thereof;

[0053] Diluent……50-80 parts;

[0054] Disintegrants……1-10 parts;

[0055] Lubricant……0.1-3 parts.

[0056] In some preferred embodiments, the pharmaceutical composition includes the following components in parts by weight:

[0057] 23-28 parts of a compound of formula (I) or a pharmaceutically acceptable salt thereof;

[0058] Diluent……60-70 parts;

[0059] Disintegrants…3-8 parts;

[0060] Lubricant……0.1-1 parts.

[0061] In some preferred embodiments, the diluent is selected from at least one of microcrystalline cellulose, lactose, mannitol, starch and dextrin.

[0062] In some preferred embodiments, the disintegrant is selected from at least one of sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone.

[0063] In some preferred embodiments, the lubricant is selected from at least one of magnesium stearate, sodium stearyl fumarate, and talc.

[0064] In some preferred embodiments, the pharmaceutical composition may further include a thickener (e.g., gelatin, gelatin arabic), a preservative (e.g., benzoate, sorbate), a binder (e.g., a mixture of powdered sugar and syrup, polyvinyl pyrrolidone), a sweetener (e.g., sucrose, aspartame), a stabilizer (e.g., ascorbic acid, sodium thiosulfate) and / or a glidant (e.g., colloidal silicon dioxide, talc).

[0065] In some preferred embodiments, the diluent is microcrystalline cellulose and pregelatinized starch.

[0066] In some preferred embodiments, the disintegrant is sodium starch glycolate.

[0067] In some preferred embodiments, the lubricant is sodium stearyl fumarate. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] FIG1 shows the effect of the diluent type on the dissolution results in Example 2 (paddle method + sinker, 50 rpm).

[0069] FIG2 shows the effect of the diluent ratio on the dissolution results in Example 2 (basket method, 75 rpm).

[0070] FIG3 shows the effect of disintegrant type on dissolution results in Example 3 (basket method, 75 rpm).

[0071] FIG4 shows the effect of the solubilizer on the dissolution results in Example 3 (basket method, 75 rpm).

[0072] FIG5 shows the dissolution test results of 20 mg capsules in Example 3 (paddle method + sinker, 75 rpm).

[0073] FIG6 shows the dissolution results of 20 mg capsules of F14 in Example 4 (paddle method + sinker, 75 rpm).

[0074] FIG7 shows the stability dissolution results of 100 mg capsules of F13 in Example 4 (paddle method + sinker, 75 rpm).

[0075] FIG8 shows the X-ray powder diffraction pattern of Form D of the sodium salt of compound TJ0113.

[0076] FIG9 shows a differential scanning calorimetry curve of Form D of the sodium salt of compound TJ0113.

[0077] FIG10 shows a thermogravimetric analysis curve of Form D of the sodium salt of compound TJ0113.

[0078] FIG11 shows the XRPD patterns of the samples before and after dry granulation in Example 5. DETAILED DESCRIPTION

[0079] The compound of Formula I or a pharmaceutically acceptable salt thereof (e.g., compound TJ0113) is also referred to herein as the "active ingredient" or "API." Those skilled in the art will appreciate that compounds of Formula I have similar properties due to their similar structures, and therefore, compounds within the scope of Formula I are suitable for use in the formulations defined herein.

[0080] The inventors of this application have discovered incompatibility issues between the active ingredient and the excipients hydroxypropylcellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, talc, sugar alcohols (particularly mannitol), and croscarmellose sodium. See the experimental details in the Examples section for details. Therefore, the formulation of the present invention does not contain these excipients with compatibility issues.

[0081] In the pharmaceutical composition of the present invention, the percentage of active ingredient in the pharmaceutical composition can be, for example, 1.0wt% to 50wt%, such as 1.0wt%, 2.0wt%, 5.0wt%, 8.0wt%, 10.0wt%, 12wt%, 15wt% to 25wt%, 30wt%, 35wt%, 40wt%, 50wt%, for example, 10.0wt% to 40wt%, or 16wt% to 30wt%, preferably 20wt% to 25wt%, or about 25wt%.

[0082] Diluents, also known as fillers, are excipients used to increase the volume or weight of solid pharmaceutical preparations. In addition to the aforementioned excipients with compatibility issues, the pharmaceutical compositions of the present invention may contain diluents known in the art, such as lactose, microcrystalline cellulose, and pregelatinized starch. To accelerate dissolution, a mixture of microcrystalline cellulose and pregelatinized starch is preferred. As demonstrated in the experiments in the Examples, the ratio of microcrystalline cellulose and pregelatinized starch has little effect on dissolution performance; for example, a ratio of 5:1 to 0.5:1 can be used, with a preferred ratio of 3:1 to 1:1. The content percentage of the diluent in the pharmaceutical composition can be, for example, 30 wt % to 90 wt %, such as 30 wt %, 35 wt %, 40 wt %, 50 wt %, 55 wt %, 60 wt %, 65 wt %, 70 wt % to 75 wt %, 80 wt %, 85 wt %, 90 wt %, for example, 40 wt % to 85 wt %, or 55 wt % to 80 wt %, preferably 65 wt % to 75 wt %, or about 70 wt %, wherein the content percentage of the pregelatinized starch in the pharmaceutical composition can be, for example, 1.0 wt % to 50 wt %, such as 1.0 wt %, 2.0 wt %, 5.0 wt %, 8.0 wt %, 10.0 wt %, 12 wt %, 15 wt % to 25 wt %, 30 wt %, 35 wt %, 40 wt %, 50 wt %, for example, 10.0 wt % to 30 wt %, or 12 wt % to 30 wt %, preferably 15 wt % to 25 wt %. The diluents used in this application are, for example, commercially available microcrystalline cellulose 102 (available from Microcellulose Weissenborn GmbH + Co. KG) and pregelatinized starch STARCH (Purchased from Colorcon).

[0083] Disintegrant refers to the auxiliary material that is used to promote solid preparation to break into fine particles rapidly in gastrointestinal fluid.Except the aforementioned auxiliary material with compatibility problem, pharmaceutical composition of the present invention can comprise disintegrant known in the art, for example sodium starch glycolate.The content percentage of disintegrant shared in pharmaceutical composition can for example be 0.1wt% to 25wt%, such as 0.1wt%, 0.5wt%, 1.0wt%, 1.5wt%, 2.0wt%, 2.5wt%, 2.7wt% to 3.0wt%, 3.2wt%, 3.5wt%, 4.0wt%, 5.0wt%, 7wt%, 8.0wt%, 10.0wt%, 12wt%, 15wt%, 20wt%, 25wt%, for example, can be 0.5wt% to 7wt%, or 1.0wt% to 5wt%, preferably 2.5wt% to 3.5wt%, or be about 3wt%. The disintegrant used in the present application is, for example, the commercially available croscarmellose sodium SD711 (available from DuPont Nutrition USA).

[0084] Lubricants refer to excipients used to reduce friction between particles and thus improve powder fluidity, which can reduce the weight and active substance content differences between preparations. The more commonly used lubricants in the pharmaceutical industry are magnesium stearate and talc, but the inventors of this application found that both belong to the aforementioned excipients with compatibility issues. Therefore, the pharmaceutical composition of the present invention requires the use of other lubricants, such as sodium stearyl fumarate. Lubricants in this application can be added internally or externally. Internal addition refers to adding during the preparation of particles to make the content of the ingredients between the particles uniform; external addition refers to adding between the prepared particles to make the number of particles contained in each unit of preparation uniform. Unless otherwise specified, the lubricant content described herein refers to the total content of internal and external lubricants. The content percentage of lubricant in the pharmaceutical composition can be, for example, 0.01wt% to 5.0wt%, such as 0.01wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.5wt% to 1.0wt%, 1.5wt%, 2.0wt%, 2.5wt%, 3.0wt%, 4.0wt%, 5.0wt%, for example, 0.1wt% to 2.0wt%, or 0.2wt% to 1.5wt%, preferably 0.5wt% to 1.0wt%, or about 1wt%. The lubricant used in this application is, for example, commercially available sodium stearyl fumarate (available from Moehs Cantabra).

[0085] In addition, the pharmaceutical composition of the present invention may contain other types of excipients as needed, as long as they do not belong to the excipients with compatibility issues mentioned above, such as adhesives, colorants, flavorings, wetting agents, preservatives, solubilizers, etc.

[0086] The present invention also relates to a pharmaceutical preparation comprising the pharmaceutical composition described herein, wherein the pharmaceutical preparation is a solid pharmaceutical preparation known in the art, such as tablets, capsules, granules, powders, pills, etc. In addition to the pharmaceutical composition, the pharmaceutical preparation may also contain other ingredients known in the art. For example, in the case of tablets, the preparation may have a coating in addition to the pharmaceutical composition; in the case of capsules, the preparation may have a capsule shell in addition to the pharmaceutical composition. The aforementioned coating or capsule shell may be a coating (e.g., a film coating, a controlled release coating) or a capsule shell (e.g., a gelatin capsule shell) known in the art, respectively, and may be obtained using methods known in the art.

[0087] The pharmaceutical compositions and pharmaceutical preparations described herein can be prepared using conventional methods in the art. For example, in the case of granules, they can be prepared using methods known in the art such as dry preparation and wet granulation. The granules can be further compressed into tablets or filled into capsule shells to form capsules.

[0088] The "halogen" and "halogen" mentioned in the present invention include fluorine, chlorine, bromine and iodine.

[0089] The term "about" as used herein refers to a range of 10% above or below the corresponding numerical value. For example, if the concentration of a certain component is about 5 mM, it indicates that its concentration is 4.5-5.5 mM; if the concentration range of a certain component is about 5-10 mM, it indicates that its concentration range is 4.5-11 mM. Unless otherwise indicated, percentages used herein are weight percentages (wt%), which are generally expressed based on the total weight of the pharmaceutical composition or formulation.

[0090] In some preferred embodiments, the solid form of the sodium salt of the TJ0113 compound (particularly the D crystal form) is prepared by the following method: obtaining the TJ0113 compound (for example, by the method described in the prior art CN115894404A), then dissolving the TJ0113 compound in a reaction medium, and adding a sodium-containing base to react.

[0091] In some preferred embodiments, the reaction medium is selected from at least one of methanol, ethanol, isopropanol, tert-butanol, acetone, acetonitrile and ethyl acetate, or a mixture of at least one of methanol, ethanol, isopropanol, tert-butanol, acetone, acetonitrile and ethyl acetate and water, for example, acetone, a mixture of acetone and water, or a mixture of acetonitrile and water.

[0092] In some preferred embodiments, the sodium-containing base is selected from at least one of sodium bicarbonate, sodium carbonate, sodium hydroxide, sodium acetate, sodium formate, sodium methoxide, sodium ethoxide and sodium tert-butoxide.

[0093] In some preferred embodiments, in the reaction system, the molar ratio of the TJ0113 compound to the sodium-containing base is 1:(0.9-1.1).

[0094] In some preferred embodiments, the TJ0113 compound is dissolved in acetone at 35-55°C (preferably 40-50°C), and a sodium bicarbonate solution is added. After the solid precipitates, the mixture is kept warm and allowed to stand for at least 20 minutes (preferably at least 30 minutes), and then cooled to room temperature to obtain a solid form of the sodium salt of the TJ0113 compound.

[0095] In some preferred embodiments, the TJ0113 compound is dissolved in acetone at 35-55° C., cooled to room temperature, and then a sodium bicarbonate solution is added with stirring. After solid precipitation, the mixture is kept warm and allowed to stand for at least 20 minutes (preferably at least 30 minutes) to obtain a solid form of the sodium salt of the TJ0113 compound.

[0096] In some preferred embodiments, the TJ0113 compound is dissolved in acetone at 35-55° C., sodium bicarbonate solution is added and stirred, and after solid precipitation, the mixture is kept warm and stirred for at least 20 minutes (preferably at least 30 minutes), and then cooled to room temperature to obtain the solid form of the sodium salt of the TJ0113 compound.

[0097] In some preferred embodiments, the TJ0113 compound is dissolved in acetone at 35-55° C., a methanol solution of sodium methoxide is added and stirred, and after solid precipitation, the mixture is kept warm and allowed to stand for at least 50 minutes (preferably at least 60 minutes), and then cooled to room temperature and stirred for at least 50 minutes (preferably at least 60 minutes) to obtain a solid form of the sodium salt of the TJ0113 compound.

[0098] In some preferred embodiments, the TJ0113 compound is dissolved in acetone at 35-55°C, sodium bicarbonate solution is added and stirred, and after solid precipitation, the mixture is kept warm and allowed to stand for at least 50 minutes (preferably at least 60 minutes) to obtain a solid form of the sodium salt of the TJ0113 compound.

[0099] The following preparation examples provide examples of the preparation method of the D crystal form, wherein the TJ0113 compound is obtained by the method described in the prior art CN115894404A.

[0100] Preparation Example

[0101] Preparation Example 1

[0102] Weigh 0.100g of TJ0113 compound and add 4ml of acetone. Heat to approximately 45°C and stir to dissolve. Add 0.223g of sodium methoxide methanol solution dropwise at approximately 45°C. A small amount of solid will form upon addition, but stir to dissolve. After stirring, solid will slowly precipitate. Maintain the mixture at approximately 45°C for 1 hour. After this, cool to approximately 20°C and stir for 1 hour. Filter and rinse with a small amount of acetone. Vacuum dry at room temperature (without heating) for approximately 20 hours. The following characterization methods confirm the crystalline form D.

[0103] Preparation Example 2

[0104] Weigh 3.00g of compound TJ0113 and add 120ml of acetone. Heat to approximately 45°C and stir to dissolve. Add 5.20g of 10% sodium bicarbonate aqueous solution dropwise at approximately 45°C. A small amount of solid will form upon addition, but stir to dissolve. After stirring, solid will slowly precipitate. Incubate at approximately 45°C for 1 hour. After this, cool to approximately 20°C and stir for 1 hour. Filter and rinse with a small amount of acetone.

[0105] The product was vacuum dried at room temperature (without heating) for about 20 hours and was confirmed to be Form D by the following characterization method.

[0106] Characterization

[0107] X-ray diffraction: The prepared Form D was analyzed using a PANalytacal Empyrean X-ray powder diffraction analyzer. The scanning parameters are as follows.

[0108] The X-ray powder diffraction patterns of Form D prepared by Preparation Examples 1 and 2 are shown in FIG8 , wherein the peak positions and intensities of the characteristic peaks are given below.

[0109] Differential Scanning Calorimetry and DSC Spectrum: The prepared D crystal form was tested using a TAQ200 / 2000 differential scanning calorimeter. The test parameters are as follows:

[0110] The DSC spectrum of crystal form D is shown in FIG9 . The differential scanning calorimetry curve of crystal form D has an endothermic peak at 183.79° C. (±3° C.) and an exothermic peak at 210.79° C. ±3° C.

[0111] Thermogravimetric analysis and TGA spectrum: The prepared D crystal form was tested using a TAQ500 / 5000 thermogravimetric analyzer. The test parameters are as follows:

[0112] The TGA spectrum of crystal form D is shown in FIG10 . The thermogravimetric analysis curve of crystal form D shows that the sample has no weight loss before decomposition.

[0113] Example

[0114] The technical solutions and embodiments of the present invention are illustrated using a capsule formulation of compound TJ0113. It should be understood that these examples are not intended to limit the scope of the present invention, particularly the active ingredient and specific dosage form. The "active ingredient" or "API" described in the Examples section is TJ0113, which is a solid sodium salt of Form D, prepared according to the aforementioned Preparation Example. The raw material product batch number is A16569-028P1.

[0115] Example 1 Compatibility test of active ingredient (API) with various excipients

[0116] The experimental steps are as follows:

[0117] 1. Take out samples at the sampling time points set in the raw material compatibility plan (see Table 1).

[0118] 2. Record the appearance of the sample. Abnormal appearance includes (1) agglomeration, (2) liquefaction, (3) discoloration

[0119] 3. Check the moisture absorption and weight gain of the sample.

[0120] 4. Use HPLC method to detect the content and related substances of the sample.

[0121] The HPLC method parameters for content and related substance detection are detailed in Table 2 below.

[0122] Common excipients used in oral solid dosage forms were mixed with the TJ0113 API in varying proportions and placed under various conditions. Samples were removed at different time points and tested for compatibility using appearance, hygroscopic weight gain, content, and related substances. According to the excipient manual, all excipients used are commonly used in oral solid dosage forms and are listed in the current edition of the Chinese Pharmacopoeia. Each excipient exhibits stable properties. To objectively evaluate the compatibility of the API with the excipients used, compatibility testing was conducted with each excipient.

[0123] The ratio of raw materials and excipients is based on the "Basic Technical Guidelines for Research on Chemical Drug Preparations" and the dosage specifications. Excipients with larger dosages (such as lactose and microcrystalline cellulose) are mixed at a ratio of 1:5 between the main drug and the diluent. Excipients with moderate dosages (such as cross-linked sodium carboxymethyl cellulose) are mixed at a ratio of 1:1 between the main drug and the disintegrant. Excipients with smaller dosages (such as magnesium stearate) are mixed at a ratio of 10:1 between the main drug and the lubricant. For information on the manufacturers of raw materials and excipient ratios for compatibility experiments, please refer to Table 1 below:

[0124] Table 1. Main sample information and raw material ratio of raw material compatibility test

[0125] Table 2. Chromatographic measurement conditions

[0126] Samples were placed under experimental conditions of high temperature (60°C), high humidity (92.5% RH), accelerated temperature (40°C / 75% RH), and illumination (visible light 5500 Lux + 500 Lux, near-UV light 85 μw / cm²). Sampling was conducted on days 0, 9, and 30. Samples were submitted for testing of relevant indicators (including appearance, moisture absorption weight gain, content, and related substances). The results were compared with those of a control sample (API). The relevant results are shown in Table 3-9 below.

[0127] Table 3. Appearance inspection results

[0128] Table 4. Moisture absorption and weight gain test results

[0129] Table 5. Content test results

[0130] *N / A: Since there was no significant change in the results of the substance at 30 days, the 10-day sample was not tested.

[0131] The test results of the relevant substances are as follows.

[0132] The following is a discussion of the experimental results on the compatibility of the API with multiple excipients:

[0133] (1) Appearance:

[0134] After being opened and placed under accelerated conditions of 40°C / 75% RH for 30 days, except for the mixed sample of API + crospovidone XL-10 which turned into red powder, the mixed samples of API and API with other excipients turned into gray powder.

[0135] After being opened and placed under high humidity 92.5% RH for 30 days, the API and API + colloidal silica The mixed samples of 200Pharma, API + magnesium stearate LIGAMED MF-2-V-MB, API + sodium stearyl fumarate, API + talc LUZENAC PHARMA, API + gelatin empty capsules and 0# opaque rich yellow (cap color number: 41.813, body color number: 41.813)-CN, US turned into gray powder, and the mixed samples of API + hydroxypropyl cellulose EXF and API + cross-linked polyvinylpyrrolidone XL-10 turned into red.

[0136] After being opened and placed under high humidity 92.5% RH for 30 days, API + pregelatinized starch STARCH The mixed samples of API+hydroxypropylcellulose EXF, API+crospovidone XL-10 and API+sodium starch glycolate VIVASTAR P showed agglomeration.

[0137] After being opened and placed under light conditions for 10 days, the surfaces of the API and the mixed samples of API and other excipients turned red, while the lower layer did not change color.

[0138] Apart from this, no significant appearance changes were observed in mixed samples of API and other excipients.

[0139] (2) Moisture absorption and weight gain:

[0140] After being opened and placed under high humidity 92.5% RH for 30 days, the API, API + microcrystalline cellulose 102, API + pregelatinized starch STARCH The mixed samples of API+hydroxypropylcellulose EXF, API+sodium starch glycolate VIVASTARP, API+cross-linked sodium carboxymethylcellulose SD711, API+cross-linked polyvinylpyrrolidone XL-10, API+magnesium stearate LIGAMED MF-2-V-MB and API+opaque yellowish gelatin empty capsule 0# had a large moisture absorption and weight gain.

[0141] (3) Content:

[0142] The content results showed that after being placed open for 30 days at high temperature of 60°C, high humidity of 92.5% RH and accelerated at 40°C / 75% RH, and after being placed under light conditions for 10 days, the content of the API and the mixed samples of API and various excipients did not change significantly.

[0143] (4) Related substances:

[0144] After being opened and placed at high temperature of 60℃ for 30 days, the mixed sample of API + mannitol 100SD showed a slight increase of related substances at RRT1.29 and RRT1.73.

[0145] The mixed sample of API + sodium starch glycolate (VIVASTAR P) showed a slight increase in related substances at RRT 1.29. The mixed sample of API + crospovidone XL-10 showed a slight increase in related substances at RRT 0.46.

[0146] After 30 days of open storage under accelerated conditions of 40°C / 75% RH, the API showed significant increases in related substances at RRT0.46, RRT1.16, RRT1.63, and RRT1.73, and slight increases at RRT1.41 and RRT1.43. The mixed sample of API + lactose Tablettose 80 showed slight increases in related substances at RRT0.89. The mixed sample of API + mannitol 100SD showed slight increases in related substances at RRT0.46, RRT0.89, RRT1.65 / 1.70, and RRT1.73. The mixed sample of API + hydroxypropylcellulose EXF showed slight increases in related substances at RRT0.46, RRT0.89, RRT1.10, RRT1.24, and RRT1.33, and significant increases at RRT1.41. The mixed sample of API + sodium starch glycolate VIVASTAR P showed slight increases in related substances at RRT1.29. The mixed sample of API + crospovidone XL-10 showed a slight increase in related substances at RRT0.46, RRT0.89 and RRT1.10, and a significant increase in related substances at RRT1.24, RRT1.33, RRT1.37 and RRT1.41. The mixed sample of 200 Pharma showed significant increases in related substances at RRT 0.46 and RRT 0.89. The mixed sample of API + magnesium stearate (LIGAMED MF-2-V-MB) showed slight increases in related substances at RRT 0.46 and RRT 1.63, and significant increases at RRT 1.16 and RRT 1.73. The mixed sample of API + sodium stearyl fumarate showed slight increases in related substances at RRT 1.16. The mixed sample of API + talc (LUZENAC PHARMA) showed slight increases in related substances at RRT 1.73.

[0147] After being opened and placed under high humidity conditions of 92.5% RH for 30 days, the API showed significant increases in related substances at RRT0.46, RRT1.16, RRT1.64 and RRT1.73, and slight increases at RRT1.41 and RRT1.74. The mixed sample of API + mannitol 100SD showed significant increases in related substances at RRT1.16. The mixed sample of API + hydroxypropyl cellulose EXF showed significant increases in related substances at RRT0.89, RRT1.10, RRT1.29 and RRT1.41, and slight increases at RRT1.33. The mixed sample of API + cross-linked polyvinylpyrrolidone XL-10 showed significant increases in related substances at RRT0.89, RRT1.10, RRT1.16, RRT1.29 and RRT1.41, and slight increases at RRT1.33. API + colloidal silicon dioxide The mixed sample of 200 Pharma showed significant increases in related substances at RRT 0.46 and RRT 1.73, and a slight increase at RRT 1.54. The mixed sample of API + magnesium stearate (LIGAMED MF-2-V-MB) showed significant increases in related substances at RRT 1.16, and a slight increase at RRT 1.73. The mixed sample of API + sodium stearyl fumarate showed a slight increase in related substances at RRT 1.16. The mixed sample of API + talc (LUZENAC PHARMA) showed a significant increase in related substances at RRT 1.16, and a slight increase at RRT 1.21.

[0148] After 10 days of exposure to light, the API showed slight increases in related substances at RRT 0.89 and RRT 1.29. The mixture of API and croscarmellose sodium SD711 showed significant increases in related substances at RRT 1.29. The mixtures of API and crospovidone XL-10 and API and sodium stearyl fumarate showed slight increases in related substances at RRT 1.29. The mixture of API and talc (LUZENAC PHARMA) showed significant increases at RRT 1.16 and slight increases at RRT 1.73.

[0149] In summary, the compatibility test results of raw materials and excipients showed that the API was unstable under high humidity, light and accelerated conditions, and the API was not stable with hydroxypropyl cellulose EXF, cross-linked polyvinylpyrrolidone XL-10, colloidal silicon dioxide, and ... Mixtures of 200 Pharma and magnesium stearate (LIGAMED MF-2-V-MB) were incompatible under accelerated conditions (40°C / 75% RH) and elevated humidity (92.5% RH). Mixtures of the API with talc (LUZENAC PHARMA) were incompatible under open air and light conditions at elevated humidity (92.5% RH). Mixtures of the API with mannitol 100SD were incompatible under elevated humidity (92.5% RH). Mixtures of the API with croscarmellose sodium SD711 were incompatible under light conditions.

[0150] Example 2: Effect of diluent on dissolution performance

[0151] Considering the inherent instability of TJ0113 under high humidity conditions and the compatibility results of raw materials and excipients, the effect of diluent type on the preparation process and capsule dissolution was investigated. The dissolution method used in this application to measure dissolution is shown in Table 10.

[0152] Table 10. Dissolution methods

[0153] This example primarily studied 100 mg capsules with a total content weight of 420 mg. No. 0 opaque yellowish gelatin capsules were used, all filled using a dry granulation process. Table 11 lists the specific ingredients for Experiments F6 and F7, which used different types of diluents. The effect of diluent type on dissolution results is shown in Table 12 and Figure 1, where dissolution method 1 was used for evaluation.

[0154] Table 11. Specific ingredients of F6 and F7

[0155] Table 12. Effect of diluent type on dissolution results (dissolution method 1)

[0156] As shown in Figure 1, the dissolution rate of F7 was significantly higher than that of F6 (especially within the first 20 minutes), indicating that the combination of microcrystalline cellulose and pregelatinized starch unexpectedly improved the dissolution rate of the API.

[0157] Because the API of the present invention has a significant increase in related substances under high humidity conditions, the pregelatinized starch STARCH (Shanda TM ) can absorb the free water that enters the tablet core and lock the water to avoid interaction with the drug. Therefore, different ratios of pregelatinized starch STARCH The specific composition is shown in Table 13, and the dissolution results are shown in Table 14 and Figure 2, where dissolution method 2 was used for evaluation.

[0158] Table 13. Specific ingredients of F11 and F12

[0159] Table 14. Effect of diluent ratio on dissolution results (dissolution method 2)

[0160] The dissolution results showed that there was no significant difference between F11 and F12, indicating that the proportion of pregelatinized starch had no significant effect on the dissolution rate. Carry out subsequent process development.

[0161] Example 3: Effect of disintegrants and solubilizers on dissolution performance

[0162] Based on the experimental results of Example 2, the disintegrant type was investigated using capsule dissolution as an indicator. The specific compositions of Experiments F7 and F10 are shown in Table 15. F10 changed the disintegrant type, while the remaining conditions remained the same as in Example 2. The dissolution results are shown in Table 16 and Figure 3, where dissolution method 2 was used for evaluation.

[0163] Table 15. Specific composition of F7 and F10

[0164] Table 16. Effect of disintegrant type on dissolution results (dissolution method 2)

[0165] From the above results, we can see that the dissolution of F10 is slightly higher than that of F7 before 30 minutes and has a smaller RSD%, so the disintegrant type is selected as sodium starch glycolate VIVASTARP.

[0166] On this basis, the effect of the addition of a solubilizer on the product's dissolution rate was further investigated. The compositions of F7 and F8 are shown in Table 17, with a solubilizer added to F8. All other conditions were the same as in Example 2. The dissolution results are shown in Table 18 and Figure 4, where dissolution method 2 was used for evaluation.

[0167] Table 17. Specific composition of F7 and F8

[0168] Table 18. Effect of solubilizer on dissolution results (dissolution method 2)

[0169] The above results show that there is no significant difference in the dissolution results between Experiments F7 and F8, indicating that the addition of Kolliphor SLS Fine, a solubilizer, has no significant effect on the dissolution rate. Therefore, it was ultimately decided not to use Kolliphor SLS Fine as a solubilizer.

[0170] The 20 mg capsules share the same formulation and process as the 100 mg capsules. The composition and dissolution results (evaluated using dissolution method 3) for the 20 mg capsules are shown in Tables 19 and 20 and Figure 5.

[0171] Table 19. Specific composition of 20 mg capsules

[0172] Table 20. Dissolution results of 20 mg capsules (dissolution method 3)

[0173] From the above data, it can be seen that the 20mg capsule can be dissolved quickly and completely, which is in line with expectations, indicating that its specific composition design is reasonable.

[0174] Example 4: Overall stability test of the preparation

[0175] The process flow of the preparation in this embodiment is as follows:

[0176] API and microcrystalline cellulose 102 are passed through 50 mesh together; the sieved API and microcrystalline cellulose 102 are then mixed with pregelatinized starch STARCH Pass through 50 mesh sieve twice; after sieving, API, microcrystalline cellulose 102, pregelatinized starch STARCH and sodium carboxymethyl starch VIVASTAR P are premixed; after the premixing, the materials are added with internal sodium stearyl fumarate for main mixing; after the main mixing is completed, dry granulation is performed; after the dry granulation, the materials are added with external sodium stearyl fumarate for total mixing; finally, the total mixed granules are filled into capsules.

[0177] The specific process flow and parameters are as follows:

[0178] 1. Weighing

[0179] Weigh TJ0113, microcrystalline cellulose 102, and pregelatinized starch STARCH according to the prescription amount. Sodium starch glycolate VIVASTARP and sodium stearyl fumarate.

[0180] 2. Sieve

[0181] First, the microcrystalline cellulose 102 and the raw material drug are sieved through a 50-mesh sieve to obtain a sieved mixture 1; then the sieved mixture 1 and the pregelatinized starch STARCH Pass both of them through a 50-mesh sieve twice; pass sodium carboxymethyl starch VIVASTAR P through a 50-mesh sieve, and pass internal and external sodium stearyl fumarate through a 30-mesh sieve respectively.

[0182] 3. Premix

[0183] Put the raw materials except sodium stearyl fumarate into the hopper of the hopper mixer and mix for 20 minutes at a mixing speed of 20 rpm.

[0184] 4. Main Mix

[0185] After the premixing is completed, sodium stearyl fumarate (internal addition) is added to the hopper and the main mixing is started. The mixture is mixed for 5 minutes at a mixing speed of 20 rpm.

[0186] 5. Dry granulation and granulation

[0187] The main mixed powder was placed in a dry granulator for granulation. The granulation parameters were: feeding speed 28 rpm, roller pressure 30 kg / cm 2The ribbons obtained by dry granulation were crushed, and the secondary granulation screen was a circular screen with an aperture of 0.8 mm, and the granulation speed was 150 rpm.

[0188] 6. Total Mixing

[0189] The granulated dry granules and the sieved sodium stearyl fumarate (externally added) were mixed in the hopper of a hopper mixer for 5 minutes at a mixing speed of 20 rpm.

[0190] 7. Capsule filling

[0191] The total mixed granules were placed in a capsule filling machine for capsule filling. The 20 mg specification was filled into 4# gelatin hollow capsule shells, and the 100 mg specification was filled into 0# gelatin hollow capsule shells.

[0192] Preliminary laboratory stability study

[0193] In order to investigate the rationality and stability of the formulation prototype, a preliminary stability study was conducted on laboratory samples.

[0194] The sample batches used for the stability study were F14 and F13. The specific composition and sample information are shown in Tables 21 and 22.

[0195] Table 21. Specific composition of F14 and F13

[0196] Table 22. Sample information for stability test

[0197] The storage conditions of the two specifications of samples F13 and F14 are the same. The specific storage conditions are shown in Table 23.

[0198] Table 23. Sample storage conditions for stability testing

[0199] The dissolution results of the stability study are shown in Table 24 and Figures 6 and 7, and the results of the stability study on related substances are shown in Table 25.

[0200] Table 24. Dissolution stability results for 20 mg and 100 mg capsules (using dissolution method 3 evaluation)

[0201] Analysis of results: From the above data, compared with the 0-day dissolution data, the dissolution of 20mg and 100mg capsules did not change significantly after being placed under 40℃ / 75%RH (closed mouth) and 40℃ / 75%RH (closed mouth + 2g desiccant) conditions for 30 days.

[0202] Results: After 30 days of storage at 40°C / 75% RH (closed), 20 mg capsules showed increases in related substances at RRT = 1.16, RRT = 1.37 / 1.38, and RRT = 1.82 / 1.73. After 30 days of storage at 40°C / 75% RH (closed), 100 mg capsules showed increases in related substances at RRT = 1.37 / 1.38. After 30 days of storage at other conditions, 20 mg and 100 mg capsules showed no significant changes in related substances.

[0203] Based on the comprehensive dissolution and related substance results, the product packaging was finally determined to be 45mL and 75mL oral solid pharmaceutical high-density polyethylene bottles and oral solid pharmaceutical polypropylene child-safe combination bottle caps with aluminum foil seals plus two pharmaceutical solid paper bags containing 1g of silica gel desiccant in English. The storage conditions are "protect from light, seal, and store at 2-8℃".

[0204] Example 5: Effect of dry granulation on the crystal form of the raw material drug

[0205] In this test case, the effect of dry granulation on the crystal form of the API was investigated. The formulation composition is shown in F13 in Table 21, and the XRPD results are shown in Figure 9. The XRPD procedure was identical to that in the preparation example. The resulting XRPD pattern is shown in Figure 11, where curve A16569-028P1 represents the API; curve 41458-088-14 / 13-20 / 100mg-BL represents the mixed powder before dry granulation; curve 41488-011-14 / 13-20 / 100mg-BL-BE represents the blank excipient before dry granulation; and curve 41458-088-14 / 13-20 / 100mg-DG-4 represents the dry granules after dry granulation. As can be seen from these curves, the main characteristic peaks in the XRPD patterns of the intermediate active sample before and after dry granulation do not change significantly, preliminarily confirming that the dry granulation process has no effect on the API crystal form.

Claims

1. A pharmaceutical composition, characterized in that The invention comprises a compound of formula I or a pharmaceutically acceptable salt thereof, a diluent, a disintegrant, a lubricant, and does not contain any of the following ingredients: hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, colloidal silicon dioxide, magnesium stearate, talc, mannitol, cross-linked sodium carboxymethyl cellulose, In the formula, R 2 For hydrogen, C 1~4 Alkyl, C 3~6 Cycloalkyl, four- to six-membered epoxyalkyl; R 3 for Among them, R 3-1 Hydrogen, hydroxyl, C 1~4 Alkyl, C 1~4 Alkoxy, C 3~6 Cycloalkyl, three to six-membered epoxyalkyl, -N(R 3- 2 R 3-2a )、-CH2C(O)R 3-2 、-CH2C(O)OR 3-2 、-CH2C(O)NR 3-2 R 3-2a , R 3-2 and R 3-2a are independently hydrogen, C 1~4 Alkyl or three to six-membered cycloalkyl, Ar is phenyl, 5- or 6-membered monocyclic heteroaryl, or is supported by at least one R 3-3 substituted 5- or 6-membered monocyclic heteroaryl, said R 3-3 For hydrogen, halogen, C 1~4 Alkyl, three to six-membered cycloalkyl, hydroxyl, C 1~4 Alkoxy, three to six membered epoxyalkyl, C 1~4 Haloalkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, -N(R 3-3a R 3-3b ) or phenyl, R 3-3a and R 3-3b are independently hydrogen, C 1~4 Alkyl or three to six-membered cycloalkyl; R 4 for Among them, R 4-1 is phenyl, and is supported by at least one R 4-11 Substituted phenyl, 5- or 6-membered monocyclic heteroaryl, at least one R 4- 11 substituted 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heteroaryl, at least one R 4-11 substituted 8- to 10-membered fused bicyclic heteroaryl, wherein R 4-11 For halogen, nitro, C 1~4 Alkyl, C 3~6 Cycloalkyl, C 1~4 Alkoxy, -N(R 4-1a R 4- 1b ), phenyl, C 1~4 Haloalkyl, C 1~4 Haloalkoxy or R 4-1a and R 4-1b are independently hydrogen, C 1~4 Alkyl or C 3~6 Cycloalkyl, and R 4-1a and R 4-1b Can bond to each other to form a ring, R 4-2 C 1~4 Alkyl, C 3~6 Cycloalkyl, or when R 2 C 1~4 When alkyl, R 4-2 With R 2 Bonded to form 4 to 8 membered rings, R 4-3 C 1~4 Alkyl or C 1~4 Alkoxy; R 5 The number of R is 0 to 5. 5 When the number is not 0, each is independently selected from halogen, nitro, nitrile, -N + (R 5-1 3. C 1~4 Haloalkyl, -C(O)OR 5-1 、-C(O)R 5-1 、-C(O)N(R 5-1 R 5-1a )、-S(O)2R 5-1 、-S(O)R 5-1 、-N=C(R 5- 1 R 5-1a ), hydroxyl, C 1~4 Alkyl, phenyl, at least one hydrogen is replaced by R 5-1 Substituted phenyl, C 1~4 Alkoxy, -N(R 5-1 R 5-1a ), -N(R 5-1 )C(O)R 5-1a 、-OC(O)R 5-1 、-OC(O)N(R 5-1 R 5-1a ) or -SR 5-1 , where R 5-1 , R 5-1a and R 5-1b are independently hydrogen, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 1~4 Alkyl, C in which at least one hydrogen is replaced by a halogen 2~4 alkenyl or C in which at least one hydrogen atom is replaced by halogen 2~4 Alkynyl.

2. The pharmaceutical composition according to claim 1, wherein the compound of formula I is TJ0113 3. The pharmaceutical composition according to claim 2, wherein the TJ0113 is in the solid form of a sodium salt represented by the following formula: Wherein X is 0.1-2, for example 1. 4 . The pharmaceutical composition according to claim 3 , wherein the solid form exhibits the following characteristic peaks at 2θ (CuKα ray) in its X-ray powder diffraction pattern: 7.06° (±0.2°) and 20.87° (±0.2°). 5 . The pharmaceutical composition according to claim 1 , comprising compound TJ0113 or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, and sodium stearyl fumarate. 6 . The pharmaceutical composition according to claim 5 , which consists of compound TJ0113 or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch, and sodium stearyl fumarate.

7. The pharmaceutical composition according to any one of claims 1 to 4, wherein the content percentage of the compound of formula I or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is 1.0 wt % to 50 wt %, the content percentage of the diluent in the pharmaceutical composition is 30 wt % to 90 wt %, the content percentage of the disintegrant in the pharmaceutical composition is 0.1 wt % to 25 wt %, and the content percentage of the lubricant in the pharmaceutical composition is 0.01 wt % to 5.0 wt %.

Citation Information

Patent Citations

  • Control method for oxidation prevention of vitamin C tablet

    CN110420189A

  • Levodropropizine-guaifenesin capsule and preparation method thereof

    CN110934872A

  • Small molecule compound with naphthylamine structure and application thereof

    CN115894404A

  • Small molecule inhibitors of MCL-1 and uses thereof

    WO2013052943A2

  • Small-molecule compound having naphthol ether structure, and use thereof

    WO2023045910A1